RE:RE:RE:Stifel GMP PresentationCandyswanwick wrote: You realize that PP was done because share price got way ahead of itself from a bs repurchase of Endo rumour, right? It's exactly what I would want management to do.
Venturing into LATAM is not something I wanted though.
Agreed Candyswanwick ... the Paladin buyback rumour was certainly part of it. I don't doubt there was a discussion but I'm also sure Goodman wasn't going to pay the price the original Endo CEO wanted. I'm sure Goodman was just testing the waters.
Also, if memory serves me correctly, we went to market twice before that $10 PP. We also received $140M CAD for the sale of the Priority Review Voucher (to Gilead) we received for the Impavido drug development.
So ... we had lots of cash even before going to market for $10 and investors were betting GUD was planning on making some huge purchase at that time. All this cash led people to think something huge was coming.
Anyway - LATAM and ROW is what Goodman was planning. In the future, we likely eye South-East Asia in some manner. Just not sure how or when. It will take a long time before that happens - if history tells us anything.
I do think the price for Paladin assets is likely getting to a more reasonable price now - whatever is left. I'm sure M8 assests are looking interesting but only at the right price ... and ... I'm sure there are 5-10 other competing assets out there that Goodman/Samira are waiting on patiently and hoping they can get something at the right price. They are in no rush - ever.
Hahaha !